Cellus Inc. has disclosed compounds acting as disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4; aggrecanase-1) and 5 (ADAMTS5; aggrecanase-2) inhibitors reported to be useful for the treatment of septic arthritis, osteoarthritis, osteonecrosis, rheumatoid arthritis and tuberculosis.